DA 9801

Drug Profile

DA 9801

Alternative Names: DA9801

Latest Information Update: 09 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Phytotherapies
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetic neuropathies

Highest Development Phases

  • Phase II Diabetic neuropathies

Most Recent Events

  • 09 Oct 2015 Phase-II clinical trials in Diabetic neuropathies in South Korea (PO)
  • 01 Oct 2013 Phase-II clinical trials in Diabetic neuropathies in USA (PO) (NCT01822925)
  • 31 Aug 2013 Dong-A ST completes a phase II trial in Diabetic neuropathies in South Korea (NCT01813799)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top